Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 12/20 | 0.41 |
| ▸ | CTSS | P25774 | 6/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3745068 | 1.00 | JAK3 (0.52) | JAK3BTKCTSKCTSSCA1 | |
| SCHEMBL8228461 | 1.00 | JAK3 (0.52) | JAK3BTKCTSKCTSSCA1 | |
| SCHEMBL10095209 | 0.88 | JAK3 (0.56) | JAK3BTKCTSKCTSSCA1 | |
| SCHEMBL6631742 | 0.88 | JAK3 (0.52) | JAK3BTKCTSKCTSSCA1 | |
| SCHEMBL836446 | 0.88 | JAK3 (0.52) | JAK3BTKCTSKCTSSCA1 | |
| SCHEMBL836447 | 0.88 | JAK3 (0.52) | JAK3BTKCTSKCTSSCA1 | |
| SCHEMBL24325842 | 0.86 | JAK3 (0.51) | JAK3BTKCTSKCTSSCA1 | |
| SCHEMBL8382498 | 0.86 | JAK3 (0.51) | JAK3BTKCTSKCTSSCA1 | |
| SCHEMBL16690492 | 0.86 | JAK3 (0.51) | JAK3BTKCTSKCTSSCA1 | |
| SCHEMBL18575519 | 0.86 | JAK3 (0.51) | JAK3BTKCTSKCTSSCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113573779-A | C10-alkylene substituted 13-membered macrolides and their use | 齐卡尼治疗股份有限公司 | 2021-10-29 | — | — | CN | disclosed |
| EP-3277686-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2020-07-22 | — | — | EP | disclosed |
| US-10072006-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2018-09-11 | — | — | US | disclosed |
| WO-2018060484-A1 | COMPOSITION COMPRISING ANTIBIOTIC COMPOUND AND AN HETEROCYCLIC COMPOUND AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2018-04-05 | — | — | WO | disclosed |
| EP-3300736-A1 | COMPOSITION COMPRISING ANTIBIOTIC COMPOUND AND AN HETEROCYCLIC COMPOUND AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2018-04-04 | — | — | EP | disclosed |
| US-20180086761-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2018-03-29 | — | — | US | disclosed |
| WO-2017203474-A1 | PROCESS FOR PREPARATION OF SACUBUTRIL INTERMEDIATE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2017-11-30 | — | — | WO | disclosed |
| US-20170298057-A1 | DEUTERATED O-SULFATED BETA LACTAM HYDROXAMIC ACIDS AND DEUTERATED N- SULFATED BETA LACTAMS | ARIXA PHARMACEUTICALS, INC. | 2017-10-19 | — | — | US | disclosed |
| EP-2431380-A2 | Macrocyclic antagonist of the motilin receptor for treatment of gastrointestinal dysmotility disorders | Tranzyme Pharma, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-7829304-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2054429-A2 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | Tranzyme Pharma, Inc. (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080206805-A1 | Compounds and Related Methods for Mutant p53 Reactivation | APPELLA DANIEL H | 2008-08-28 | — | — | US | disclosed |
| US-20080206805-A1 | Compounds and Related Methods for Mutant p53 Reactivation | APPELLA DANIEL H | 2008-08-28 | — | — | US | disclosed |
| US-20080206805-A1 | Compounds and Related Methods for Mutant p53 Reactivation | APPELLA DANIEL H | 2008-08-28 | — | — | US | disclosed |
| WO-2008033328-A2 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | TRANZYME PHARMA, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-7329775-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329775-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329775-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050245616-A1 | Compounds and related methods for mutant p53 reactivation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-03 | — | — | US | disclosed |
| WO-2005042481-A2 | COMPOUNDS AND RELATED METHODS FOR MUTANT p53 REACTIVATION | NORTHWESTERN UNIVERSITY (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298057-A1 | DEUTERATED O-SULFATED BETA LACTAM HYDROXAMIC ACIDS AND DEUTERATED N- SULFATED BETA LACTAMS | DDOST, LBR, STS | JAK3 1663/4885BTK 253/4885CTSK 820/4885 |
| US-10072006-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | NQO1, PEPD, LCT | JAK3 4563/4885BTK 239/4885CTSK 315/4885 |
| US-20050245616-A1 | Compounds and related methods for mutant p53 reactivation | TP53, TP53BP1, MDM2 | JAK3 4205/4885BTK 4666/4885CTSK 1610/4885 |
| US-20180086761-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | NQO1, PEPD, BBOX1 | JAK3 4533/4885BTK 150/4885CTSK 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.